ReviewInternational journal of molecular sciences2021
Role of Retinal Amyloid-β in Neurodegenerative Diseases: Overlapping Mechanisms and Emerging Clinical Applications.
Review in International journal of molecular sciences, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 54 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
54 citing papers in PubMed, 66 citations in OpenAlex.
- Retinal proteomics in neurodegeneration: Insights into ocular and brain disorders.Neural regeneration research · 2026Article
- Dementia Risk After Glaucoma Surgery and Medical Therapy: A Multicentre Real-World Cohort Study.International journal of geriatric psychiatry · 2026Article
- Retinitis pigmentosa elicits neurodegeneration within the visual pathway in REEP6 knockout mice.Neural regeneration research · 2026Article
- Tropomyosin-Related Kinase Receptor Type B Agonism in Geographic Atrophy-The Translational Challenges from Preclinical Data to a First-in-Human Trial.Ophthalmology science · 2026Article
- Cytokine Gene Polymorphisms in Primary Glaucoma: Insights into Inflammatory Pathways and Future Directions.Molecular neurobiology · 2026Review
- Targeting Neuroinflammation and Oxidative Stress to Slow Neurodegeneration in the Visual System.Journal of clinical medicine · 2026Review
- Microglial regulation of synaptic plasticity in transsynaptic degeneration of glaucoma.Frontiers in neuroscience · 2026Review
- Elevated Neurodegeneration Markers in the Aqueous Humor of Primary Open Angle and Normal Tension Glaucoma Patients Correlate With Disease Severity.Investigative ophthalmology & visual science · 2025Article
- Association of retinal layer thickness with brain volume and cortical thickness in older adults.Scientific reports · 2025Article
- Beyond the Eye: Glaucoma and the Brain.Brain sciences · 2025Review
- Expression of Reelin, Aβ1-42, Tau and FTH1 in Idiopathic Epiretinal Membranes: Exploring the Link Between Reelin and Neurodegenerative Biomarkers.Biomolecules · 2025Article
- Atorvastatin Alleviates Age-Related Macular Degeneration via AIM2-Regulated Pyroptosis.Inflammation · 2025Article
- Serum Uric Acid and Intermediate Age-Related Macular Degeneration: A Nationally Representative Study in the United States.Translational vision science & technology · 2025Article
- Biomolecular Aspects of Reelin in Neurodegenerative Disorders: An Old Candidate for a New Linkage of the Gut-Brain-Eye Axis.International journal of molecular sciences · 2025Review
- HSV-1 Infection in Retinal Pigment Epithelial Cells: A Possible Contribution to Age-Related Macular Degeneration.Viruses · 2025Review
- Ceruloplasmin and Ferritin Changes in Ocular Fluids from Patients with Vitreoretinal Diseases: Relation with Neuroinflammation and Drusen Formation.International journal of molecular sciences · 2025Article
- Assessment of individual retinal layer thickness and vascular changes in Alzheimer's disease.Scientific reports · 2025Article
- Exploring Retinal Neurodegeneration in Alzheimer's Disease: A Molecular and Cellular Perspective.Neurotoxicity research · 2025Review
- Unraveling the role of neuregulin-mediated astrocytes-OPCs axis in the pathogenesis of age-related macular degeneration and Parkinson's disease.Scientific reports · 2025Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
Abstract
Amyloid-β (Aβ) accumulations have been identified in the retina for neurodegeneration-associated disorders like Alzheimer's disease (AD), glaucoma, and age-related macular degeneration (AMD). Elevated retinal Aβ levels were associated with progressive retinal neurodegeneration, elevated cerebral Aβ accumulation, and increased disease severity with a decline in cognition and vision. Retinal Aβ accumulation and its pathological effects were demonstrated to occur prior to irreversible neurodegeneration, which highlights its potential in early disease detection and intervention. Using the retina as a model of the brain, recent studies have focused on characterizing retinal Aβ to determine its applicability for population-based screening of AD, which warrants a further understanding of how Aβ manifests between these disorders. While current treatments directly targeting Aβ accumulations have had limited results, continued exploration of Aβ-associated pathological pathways may yield new therapeutic targets for preserving cognition and vision. Here, we provide a review on the role of retinal Aβ manifestations in these distinct neurodegeneration-associated disorders. We also discuss the recent applications of retinal Aβ for AD screening and current clinical trial outcomes for Aβ-associated treatment approaches. Lastly, we explore potential future therapeutic targets based on overlapping mechanisms of pathophysiology in AD, glaucoma, and AMD.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.